memo-inOncology – SPECIAL ISSUE
Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research.
The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.
Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.
memo – inOncology SPECIAL ISSUE
Congress Report ASCO Lung Cancer 2022
A GLOBAL DIGEST ON APPROACHES IN LUNG CANCER
Report from the ASCO Congress,
3rd-7th June 2022
memo – inHematology SPECIAL ISSUE
Congress Report EHA 2022
Report from the European Hematology Association (EHA) Congress,
9th–12th June 2022
All videointerviews from ASCO Lung Cancer 2022
John Varlotto summarizes the insights that have been obtained based on recent studies regarding immunotherapy plus chemoradiation in patients with unresectable, locally advanced stage III non-small cell lung cancer, explains the different effect observed with pembrolizumab and nivolumab and how these results compare to existing data. He cautions against using the impressive pathologic complete response rates with neoadjuvant chemoimmunotherapy to the unresectable setting due to the lack of long-term survival rates with neo-adjuvant chemo/immunotherapy and the impressive 47.5 median overall survival noted with concurrent chemo/radiotherapy followed by consolidative durvalumab in the Pacific Trial.
Jessica Donington highlights the most promising agents currently investigated in the neoadjuvant setting in patients with resectable NSCLC, how the “intensity” of neoadjuvant treatment affects the outcomes and discusses if neoadjuvant chemo-immunotherapy is the new standard of care. She outlines which variables related to surgery itself are determinants of the success of curative surgery and which biomarkers are on the rise to guide therapy.
All videointerviews from EHA 2022
Naval Daver overviews the most promising new agents in the treatment of AML, how existing drugs can blend into new regimens and how the prognosis of patients with AML will evolve in the years to come. Finally, he talks about risk factors for ICI-related pneumonitis development and if pneumonitis increases mortality in AML patients.
Jorge Castillo explains the most meaningful diagnostic criteria for WM, give insights into the “real-world” treatment of WM with zanubrutinib, bortezomib and other treatment strategies and how to sequence therapies in WM. He explains promising modes of action of new agents in the treatment of WM and depicts his personal highlights from this year’s EHA congress.
Wojciech Jurczak outlines what can be achieved with the current standard treatments in the setting of follicular lymphoma, which findings have been observed for PI3K inhibitor therapy in the TIDAL study and were we are today with respect to CAR-T cell therapy for patients with follicular lymphoma.
Constantine Tam highlights the most relevant findings presented at EHA 2022 as well as promising modes of action of new agents in the treatment of indolent lymphomas. He explains how resistance to BTK inhibitors can be addressed in B-cell malignancies while giving an outlook on a BTK protein degrader and finally summarizes the long-term results obtained with zanubrutinib compared to ibrutinib in the ASPEN trial in patients with WM.
Shirley D’Sa discusses how the treatment and especially the prognosis of patients with WM evolved over the last decades, which approaches can be used to successfully treat patients with MYD88WTWM, how the interaction between WM cells and the bone marrow microenvironment can be used to develop new ways to overcome treatment resistance and finally explains how often the Binge-Neel Syndrome happens, how its diagnosed and how it should be treated.
A CONGRESS RESOURCE
For Oncologists and Haematologists